Dr. Soileau discusses the clinical role of continuous subcutaneous Vyalev (foscarbidopa/foslevodopa) therapy for patients with Parkinson’s disease experiencing motor fluctuations despite optimized oral treatment. He reviews clinical trial data demonstrating increased “on” time without troublesome dyskinesia and explains how continuous subcutaneous delivery bypasses gastrointesti...
Subscribe in seconds and receive Innovations in Clinical Neuroscience's news feed updates in your inbox, on your phone or even read them from your own news page here on follow.it.
You can select the updates using tags or topics and you can add as many websites to your feed as you like.
And the service is entirely free!
Follow Innovations in Clinical Neuroscience: ICNS Home - Innovations in Clinical Neuroscience